Who
Daniel Tasse
Director
Company insider
Files Form 4 as: Director, Regenxbio; Chief Executive Officer, DBV Technologies; Director, Bellerophon Therapeutics.
In numbers
- Trades disclosed
- 31
- Buys
- 2
- Sells
- 0
- Bought
- $314K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 19 Feb 2015
- Last trade
- 29 May 2026
- Last filed
- 2 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 May 2026filed 2 Jun 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —9,807 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —46,600 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —46,600 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —9,807 at $0.00 | filing |
| 21 Nov 2025filed 24 Nov 2025 | DBVT DBV Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —964,000 at $0.00 | filing |
| 30 May 2025filed 3 Jun 2025 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —39,815 at $0.00 | filing |
| 30 May 2025filed 3 Jun 2025 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —7,768 at $0.00 | filing |
| 4 Dec 2024filed 5 Dec 2024 | DBVT DBV Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —813,200 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —24,454 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —4,790 at $0.00 | filing |
| 8 Mar 2024filed 11 Mar 2024 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Bought | $14K17,094 at $0.83 | filing |
| 20 Nov 2023filed 22 Nov 2023 | DBVT DBV Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —806,672 at $0.00 | filing |
| 2 Jun 2023filed 6 Jun 2023 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,892 at $0.00 | filing |
| 2 Jun 2023filed 6 Jun 2023 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —3,486 at $0.00 | filing |
| 21 Nov 2022filed 14 Aug 2023 | DBVT DBV Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —764,386 at $0.00 | filing |
| 3 Jun 2022filed 7 Jun 2022 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —15,324 at $0.00 | filing |
| 3 Jun 2022filed 7 Jun 2022 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —3,010 at $0.00 | filing |
| 22 Nov 2021filed 24 Nov 2021 | DBVT DBV Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —274,000 at $0.00 | filing |
| 4 Jun 2021filed 8 Jun 2021 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 29 May 2020filed 2 Jun 2020 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
News
Head-To-Head Review: DBV Technologies (NASDAQ:DBVT) vs. Arrowhead Pharmaceuticals (NASDAQ:ARWR)DBVT · dailypolitical.com · 21 Oct 2026DBV Technologies (NASDAQ:DBVT) Sets New 52-Week Low – What's Next?DBVT · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Daniel Tasse; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.